Parse and Graph build immune perturbation atlas – single‑cell scale

Parse Biosciences and Graph Therapeutics struck a strategic partnership to create a large‑scale immune cell perturbation atlas using Parse’s GigaLab single‑cell sequencing and Graph’s lab‑in‑the‑loop patient‑derived disease models. The collaboration will profile hundreds of millions of cells under systematic perturbations to map immune and tissue interactions implicated in immune diseases. Parse, now part of Qiagen, said the atlas will serve drug developers as an infrastructure asset to reduce biological uncertainty and accelerate target validation and translational decision‑making.